USA - engelsk - NLM (National Library of Medicine)

eli lilly and company - galcanezumab (unii: 55khl3p693) (galcanezumab - unii:55khl3p693) - emgality is indicated for the preventive treatment of migraine in adults. emgality is indicated for the treatment of episodic cluster headache in adults. emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients [see warnings and precautions (5.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to emgality during pregnancy. healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com. risk summary there are no adequate data on the developmental risk associated with the use of emgality in pregnant women. administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; water for injections; histidine; sodium chloride; polysorbate 80 - emgality is indicated for the prophylaxis of migraine in adults.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; water for injections; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate - emgality is indicated for the prophylaxis of migraine in adults.

Den europeiske union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - migræneforstyrrelser - analgesics, galcanezumab - emgality er indiceret til forebyggelse af migræne hos voksne, der har mindst 4 migræne dage per måned.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - disturbi fl-emigranja - analgesics, galcanezumab - emgality huwa indikat għall-profilassi ta ' l-emigranja fl-adulti li jkollhom mill-anqas 4-emigranja jiem kull xahar.

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - migraine stoornissen - analgesics, galcanezumab - emgality is geïndiceerd voor de profylaxe van migraine bij volwassenen die minstens 4 dagen migraine, - per maand.

Den europeiske union - ungarsk - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - migrénes betegségek - analgesics, galcanezumab - emgality javasolt a profilaxis, a migrén, a felnőttek, akik legalább 4 migrén nap / hónap.

Den europeiske union - tysk - EMA (European Medicines Agency)

eli lilly nederland b.v. - galcanezumab - migräne-störungen - analgesics, galcanezumab - emgality ist angezeigt für die prophylaxe der migräne bei erwachsenen, die mindestens 4 migräne-tage pro monat.

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - galcanezumabum - lösung zur injektion in einen stift ausgefüllt - galcanezumabum 120 mg, histidinum, histidini hydrochloridum monohydricum, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - eine prophylaktische behandlung der migräne - biotechnologika

Israel - engelsk - Ministry of Health

eli lilly israel ltd, israel - galcanezumab - solution for injection - galcanezumab 120 mg / 1 ml - galcanezumab - emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.